key: cord-0925976-id3ed22n
authors: Jordan, Stanley C.; Shin, Bong-Ha; Gadsden, Terry-Ann M.; Chu, Maggie; Petrosyan, Anna; Le, Catherine N.; Zabner, Rachel; Oft, Jillian; Pedraza, Isabel; Cheng, Susan; Vo, Ashley; Ammerman, Noriko; Plummer, Jasmine; Ge, Shili; Froch, Max; Berg, Anders; Toyoda, Mieko; Zhang, Ruan
title: T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals
date: 2021-09-16
journal: Cell Mol Immunol
DOI: 10.1038/s41423-021-00767-9
sha: d90a5c49dabb9b7476c94df5edbd4665c11b2f2b
doc_id: 925976
cord_uid: id3ed22n

nan

mutation have accelerated replication, increasing infectivity. Data on the effectiveness of SARS-CoV-2vaccines against the Delta variant are limited [7] .

We developed a whole-blood assay to detect SARS-CoV-2specific T cells. Analysis of cytokine production in stimulated T cells confirmed that IL-2 and TNF-α are consistent markers for activated CD4+ T cells, while activated CD8+ T cells mainly produce TNF-α and IFN-γ. After incubating whole blood with a SARS-CoV-2 Spike peptide pool, we were able to identify Spikereactive T cells by dual-cytokine gating ( Supplementary Fig. S1 ). In this assay, healthy individuals with no history of SARS-CoV-2 infection demonstrated no significant T cell response to the SARS-CoV-2 spike peptide. However, T cells from SARS-CoV-2-infected or vaccinated individuals showed substantial spike-specific CD4+ and CD8+ T cell populations.

Next, we examined memory T cell immunity against SARS-CoV-2 in 134 patients with documented SARS-CoV-2 infection (Supplementary Table S1 and Supplementary Fig. S2 ). T cell immune responses to peptide pools of 5 major SARS-CoV-2 proteins (Spike, VME, NCAP, AP3A, and NS7A) were analyzed. For healthy control individuals, no significant CD4+ T cell responses to the 5 SARS-CoV-2 proteins were seen (Fig. 1A , IL-2+/TNF-α+ (%) in CD4+ <0.05%, mean = 0.01%). However, 20% of healthy individuals showed heterogeneous TNF-α+/IFN-γ+CD8+ T cell (>0.05%) responses to the 5 SARS-CoV-2 proteins, which could represent cross-reactivity among CD8+ T cells generated during previous endemic coronavirus infection (Fig. 1B) [8] . Based on the background level of the CD4+ T cell response in healthy controls, we set 0.05% dual-positive CD4+ and CD8+ T cells as the cutoff level for identifying positive T cell immunity against SARS-CoV-2. Overall, we observed that 88% (30 of 34) of infected patients had either positive CD4+ or CD8+ T cell immunity to one or more of the 5 SARS-CoV-2 proteins. Most patients showed positive CD4+ T cell immunity (85%, 29 of 34), and CD4+ T cells demonstrated immunodominant responses to Spike peptides, as previously described [8] (Fig. 1A ). CD8+ T cells showed similar responses to the 5 proteins.

Next, we analyzed Spike-specific CD4+/CD8+ immune responses induced by the Pfizer BNT162b2 vaccine. We compared Spike-specific T cell immunity among 19 healthy controls, 38 infected patients, and 38 vaccinated individuals 1 month after the 2nd vaccine dose (Fig. 1A , B). No healthy unvaccinated individuals showed positive CD4+ T cell immunity against SARS-CoV-2, but infected patients and vaccinated individuals demonstrated substantial spike-specific CD4+ T cell immunity, with rates of 87% (33 of 38) and 89% (34 of 38), respectively. CD8+ T cells from healthy controls, infected patients, or vaccinated individuals showed 21% (4 of 19), 34% (13 of 38), and 58% (22 of 38) positivity for immune responses against SARS-CoV-2 spike peptides, respectively. Therefore, the Pfizer BNT162b2 vaccine induced T cell reactivity to Spike-specific peptides that was equivalent to that seen in infected patients after recovery.

Serum from SARS-CoV-2 patients was submitted for clinical nucleoprotein IgG titering. In 25 patients with nucleocapsid IgG positivity, we analyzed the association with CD4+ T cell immunity to the 5 SARS-CoV-2 peptides (the highest response was compared). Although T cell immunity was not nucleocapsid-specific, there was a significant association between CD4+ T cell immunity and nucleocapsid IgG titers (p = 0.022; R = 0.457; Fig. 1C ).

We then examined Spike-specific IgG levels in 80 SARS-CoV-2infected patients and compared them to Spike-specific T cell immunity results. In total, 72.58% of patients with detectable Spike-specific CD4+ T cells were positive for Spike-specific IgG. Among patients without detectable Spike-specific T cell immunity, 61.11% also were negative for Spike-specific IgG by serology. In 13 patients with high Spike-specific CD4+ T cell immunity (IL-2+/TNF-α+ (%) in CD4+ ≥0.3%), we also observed a strong correlation between T cell immunity and the level of Spike-specific IgG (p = 0.0316; R = 0.5288; Fig. 1D ).

The Alpha (B.1.1.7) variant contains the E484K mutation, which establishes resistance to serologic responses in infected individuals [4] . To determine whether this VOC evades T cell immunity, we analyzed 19 infected/recovered patients and 18 healthy vaccinated individuals for CD4+/CD8+ T cell responses against the Alpha variant Spike protein. As shown in Fig. 1E , F, there were no significant reductions in CD4+/CD8+ T cell responses to the Alpha variant Spike peptides compared to those to the ancestral Spike peptides (mean of infected patients: 0.23% ancestral vs. 0.18% Alpha variant; mean of vaccinated individuals: 0.16% ancestral vs. 0.14% Alpha variant). In addition, nearly identical CD4+ and CD8+ T cell responses to the Delta variant peptides and SARS-CoV-2 spike peptides were detected in 11 healthy BNT162b2-vaccinated individuals (Fig. 1E, F) . In summary, T cell memory induced by SARS-CoV-2 infection or vaccination produces similar immune responses against the Alpha and Delta variants. This suggests protective immunity against Alpha and Delta variant infection and possibly infection by other VOCs [9] . Herein, we present data identifying memory T cells with specificity and accuracy for the detection of CD4+/CD8+ T cell responses to SARS-CoV-2 peptides that differentiate infected and vaccinated individuals from those not exposed to SARS-CoV-2. In addition, analysis of T cell responses to VOCs (Alpha and Delta) showed that SARS-CoV-2 infection and vaccination with BNT162b2 elicited equivalent T cell responses.

The development of dormancy in memory T cells, B cells, and plasma cells is a natural temporal evolution after infection and/or vaccination that produces populations that can rapidly be activated upon re-exposure to SARS-CoV-2 and are likely to have an important role in preventing or modifying infection by SARS-CoV-2 VOCs [9, 10] . An important consideration in this regard is the dissipation of humoral immunity over time. IgG responses are critical for sterilizing immunity. However, T cell immunity does require an infection to reactivate memory responses. This may result in mild or asymptomatic infections that would be considered "breakthrough" infection. Thus, the level and robustness of T cell memory responses would likely affect the clinical manifestations of the disease.

Request for data relevant to the manuscript will be considered after assessment and review.

SARS-CoV-2 variants and vaccines

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

A long-term perspective on immunity to COVID

Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection

Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections

Longitudinal analysis of antibody decay in convalescent COVID-19 patients

Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

T-cells in COVID-19 -united in diversity

AP: Involved in the performance of the antibody assays. CNL: Involved in gathering and analyzing data and writing the manuscript. RZ: Involved in gathering and analyzing data for the manuscript. JO: Involved in gathering and analyzing data for the manuscript. IP: Involved in gathering and analyzing data for the manuscript. SC: Provided technical and editing support for the project. AV: Provided support for developing the protocol and regulatory documents. NA: Provided regulatory support for the development of the project. JP: Provided laboratory support and editing for the project. SG: Helped in assay development and implementation. MF: Aided in the design and performance of assays. AB: Aided in the development and implementation of antibody assays and the interpretation of data. MT: Helped in the development and implementation of the T cell assay

The funding for this study was derived entirely from internal resources at Cedars-Sinai Medical Center, including funding from the Borstenin Family Foundation, Los Angeles.

The authors declare no competing interests.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41423-021-00767-9.Correspondence and requests for materials should be addressed to Stanley C. Jordan.Reprints and permission information is available at http://www.nature.com/ reprints